> Luminex ($LMNX) submitted its 510(k) applications to the FDA for its HSV 1&2 test. Statement
> The companion diagnostics market is expected to reach $5.6 billion in 2019, according to a new report. Release
> San Diego, CA-based Biocept ($BIOC) launched its test for BRAF mutations in patients with melanoma. More
> Curetis is kicking off the next phase in a trial for a second-generation version of its diagnostic system for lower respiratory tract (LRT) infections. Statement
> Progenetics inked a deal with OncoDNA to distribute the company's products in Israel. Story (reg. req.)
And Finally… A new study comparing Ebola diagnostics approved for emergency use found that a test from bioMérieux's BioFire Diagnostics unit was faster and easier to use than other products. Abstract